Drug Profile
Research programme:antibacterial therapeutics - Spexis
Latest Information Update: 16 Feb 2022
Price :
$50
*
At a glance
- Originator AMP Therapeutics
- Class Antibacterials; Peptide antibiotics
- Mechanism of Action Bacterial protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gram-negative infections
Most Recent Events
- 28 Jun 2018 No recent reports of development identified for research development in Gram-negative-infections in Germany
- 05 Jan 2012 Early research in Gram-negative infections in Germany (unspecified route)